ArticleThe oncologist2026
Temozolomide reconsidered: Real-World evidence in resistant melanoma cases.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors have transformed outcomes in melanoma and other aggressive malignancies. However, subsequent lines of therapy remain limited: modest efficacy, lack of publicly funded options, and declining performance status frequently restrict clinicians' choices. In this context, temozolomide has re-emerged as a feasible bridge therapy, with emerging evidence suggesting synergistic activity when used alongside anti-PD-1 agents. Here, we describe two cases of single-agent temozolomide administered after progression on prior systemic therapies, including anti-PD-1 and, in one case, targeted therapy, both demonstrating meaningful clinical responses and great patient tolerability. We also briefly discuss how these observations may support further exploration of temozolomide within modern treatment sequencing strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.